J Lung Cancer.  2008 Dec;7(2):71-74. 10.6058/jlc.2008.7.2.71.

Mutational Analysis of JAK1 Exons 10 and 13 in Non-small Cell Lung Cancers

• Oh JE
• Yoon HK
• Woo IS
• Kim SJ
• Yoo NJ
• Lee SH

• KMID: 2200029
• DOI: http://doi.org/10.6058/jlc.2008.7.2.71

Abstract

PURPOSE : JAK kinases play important roles not only in normal cellular processes, but they are also important in tumor development. A recent study identified two somatic mutations of JAK1 in leukemia cells that were detected in exon 10 (p.T478S) and exon 13 (p.V623A). The aim of this study was to see whether the JAK1 mutations in these exons occur in non-small cell lung cancers (NSCLC).
MATERIALS AND METHODS
: We analyzed the exons 10 and 13 of JAK1 for detecting somatic mutations in NSCLC by performing polymerase chain reaction (PCR) and single-strand conformation polymorphism (SSCP) assay.
RESULTS
: The SSCP analysis revealed no evidence of somatic mutation in the DNA sequences of JAK1 exon 10 and exon 13 in the 47 NSCLCs.
CONCLUSION
: The data presented here indicate that the JAK1 exons 10 and 13 may not be somatically mutated in human NSCLCs, and this suggests that the JAK1 mutation in exons 10 and 13 may not play an important role in the tumorigenesis of NSCLCs

Keyword

Non-small cell lung cancer; JAK1; Mutation

MeSH Terms

Base Sequence
Carcinoma, Non-Small-Cell Lung
Cell Transformation, Neoplastic
Exons
Humans
Janus Kinases
Leukemia
Lung
Lung Neoplasms
Polymerase Chain Reaction
Polymorphism, Single-Stranded Conformational
Janus Kinases

Figure

• 

  Fig. 1. Representative SSCP of the JAK1 gene in the non-small cell lung cancers. The exon 10 of the JAK1 gene was amplified by PCR with using a specific primer set. The PCR products from the representative cases of non-small cell lung cancers were visualized on SSCP. The SSCP of the DNA from the non-small cell lung cancers (T) shows no aberrant bands as compared to that of the SSCPs from the normal tissues (N).

Reference

References

1. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene. 2000; 19:5662–5679.

2. Verma A, Kambhampati S, Parmar S, Platanias LC. Jak family of kinases in cancer. Cancer Metastasis Rev. 2003; 22:423–434.

3. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2000; 19:6613–6626.

4. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997; 278:1309–1312.

5. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythae-mia vera. Nature. 2005; 434:1144–1148.

6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352:1779–1790.

7. Xiang Z, Zhao Y, Mitaksov V, et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood. 2008; 111:4809–4812.

8. Seki Y, Suzuki N, Imaizumi M, et al. STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT3. Int J Oncol. 2004; 24:931–934.

9. Soung YH, Lee JW, Kim SY, et al. Somatic mutations of CASP3 gene in human cancers. Hum Genet. 2004; 115:112–115.

10. Lee SH, Shin MS, Park WS, et al. Alterations of Fas (Apo-1/CD95) gene in nonsmall cell lung cancer. Oncogene. 1999; 18:3754–3760.

11. Lee SH, Shin MS, Kim HS, et al. Alterations of the DR5/TRAIL receptor 2 gene in nonsmall cell lung cancers. Cancer Res. 1999; 59:5683–5686.

12. Shin MS, Kim HS, Lee SH, et al. Alterations of Fas-pathway genes associated with nodal metastasis in nonsmall cell lung cancer. Oncogene. 2002; 21:4129–4136.

13. Lee JW, Soung YH, Nam SW, Lee JY, Yoo NJ, Lee SH. Mutational analysis of proapoptotic BAD gene in nonsmall cell lung cancer. J Lung Cancer. 2006; 5:35–38.

14. Soung YH, Lee UW, Moon SW, et al. Mutational analysis of caspase-7 and 8 genes in nonsmall cell lung cancer. J Lung Cancer. 2005; 4:38–41.

15. Soung YH, Lee JW, Kim SY, et al. Mutational analysis of proapoptotic caspase-9 gene in common human carcinomas. APMIS. 2006; 114:292–297.

16. Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science. 2003; 300:949.

17. Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005; 65:7591–7595.

18. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304:1497–1500.

19. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med. 2004; 350:2129–2139.

20. Arteaga CL, Moulder SL, Yakes FM. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol. 2002; 29:4–10.

21. McDermott U, Sharma SV, Dowell L, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007; 104:19936–19941.